Innovation1 Biotech (Innovation1 Biotech) Cash-to-Debt : 0.22 (As of Aug. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Innovation1 Biotech Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Innovation1 Biotech's cash to debt ratio for the quarter that ended in Aug. 2023 was 0.22.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Innovation1 Biotech couldn't pay off its debt using the cash in hand for the quarter that ended in Aug. 2023.

The historical rank and industry rank for Innovation1 Biotech's Cash-to-Debt or its related term are showing as below:

IVBT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02 Med: 0.86 Max: No Debt
Current: 0.22

During the past 9 years, Innovation1 Biotech's highest Cash to Debt Ratio was No Debt. The lowest was 0.02. And the median was 0.86.

IVBT's Cash-to-Debt is ranked worse than
71.13% of 523 companies
in the Diversified Financial Services industry
Industry Median: 5.45 vs IVBT: 0.22

Innovation1 Biotech Cash-to-Debt Historical Data

The historical data trend for Innovation1 Biotech's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Innovation1 Biotech Cash-to-Debt Chart

Innovation1 Biotech Annual Data

Trend

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

Cash-to-Debt

Get a 7-Day Free Trial

0.25

0.02

0.86

0.31

0.22

Innovation1 Biotech Quarterly Data
	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23
Cash-to-Debt	Get a 7-Day Free Trial															0.31	0.02	1.63	0.64	0.22

Competitive Comparison of Innovation1 Biotech's Cash-to-Debt

For the Shell Companies subindustry, Innovation1 Biotech's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innovation1 Biotech's Cash-to-Debt Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Innovation1 Biotech's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Innovation1 Biotech's Cash-to-Debt falls into.

Innovation1 Biotech Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Innovation1 Biotech's Cash to Debt Ratio for the fiscal year that ended in Aug. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.05	/	(0.01	+	0.219)
	=	0.22

Innovation1 Biotech's Cash to Debt Ratio for the quarter that ended in Aug. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.05	/	(0.01	+	0.219)
	=	0.22

Innovation1 Biotech (OTCPK:IVBT) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Innovation1 Biotech Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Innovation1 Biotech's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Innovation1 Biotech (Innovation1 Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Innovation1 Biotech Inc (OTCPK:IVBT) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

40 Wall Street, Suite 2701, New York, NY, USA, 10005

Website

https://www.innovation1bio.com

Innovation1 Biotech Inc is a shell company.

Executives

Grays Peak Llc	10 percent owner	8 THE GREEN, STE. A, DOVER DE 19803
Timothy Orr	director, 10 percent owner, officer: President	4010 TANAGER LANE, #A, MEAD WA 99021
Darren Long	director, 10 percent owner, officer: CEO & Secretary	4010 TANAGER LANE, #A, MEAD WA 99021
Brian Martinho	director, 10 percent owner, officer: Treasurer	4010 EAST TANAGER LANE, MEAD WA 99021